Everett Cunningham knows that innovation in healthcare isn’t just about technology—it’s about access. As Chief Commercial Officer at Illumina, he leads the company’s global commercial strategy, ensuring that life-saving genomic advancements reach more people worldwide. His approach is deeply personal, shaped by a career in healthcare spanning over two decades and a firsthand understanding of the consequences of limited access to preventive care. With a focus on expanding market reach and strategic partnerships, Cunningham is driving Illumina’s mission to transform human health through genomics.
Born and raised in Waterloo, Iowa, Cunningham grew up witnessing the disparities in healthcare that continue to shape his leadership today. He earned a bachelor’s degree in economics from Northwestern University before embarking on a career that would place him at the forefront of healthcare technology and life sciences. Prior to joining Illumina in 2024, he served as Chief Commercial Officer at Exact Sciences, overseeing marketing, sales, and customer service. His leadership experience extends across Quest Diagnostics, GE Healthcare, and Pfizer, where he spent 21 years in various senior roles. At Illumina, Cunningham’s work centers on scaling commercial operations and expanding the company’s reach in global markets, reinforcing its commitment to early disease detection and personalized medicine.
Cunningham’s dedication to healthcare extends beyond his corporate role. A staunch advocate for preventive care, he openly shares his personal experiences with cancer screening to highlight the importance of early detection. His commitment is also evident in his role on the Board of Directors for CitiWide Harm Reduction, a community-based organization supporting marginalized populations. By combining industry expertise with personal conviction, Cunningham is not just shaping commercial strategy—he is championing a future where more people have access to the care they need before it’s too late.